Re: test kits from the Feb 13 CC:
Emily Lee: Is there a
Re: test kits from the Feb 13 CC:
Emily Lee: Is there a timeframe where this can be developed for the test tubes?
Dr. Hal Hanes: Yeah. I can give you an estimate. I certainly do not know. It would require us
taking the peptides that Eric produces and analyze this to make sure they are
proper ones. It is raising antibodies to them in animals. This can be done
relatively quickly. There are lots of animals where it can be done that way. Use
those antibodies as the analytical reagent. In other words, we put them on a
strip. It is like a diabetes strip, except for infectious diseases. We have a lot of
expertise in this. We put them on a strip. We have a control line. We put the
oral fluid after it has been diluted. Let it run up on the strip. The line with the
antibodies to the coronavirus, if there is a coronavirus in that sample, will light
up. The control line will light up. We will be able to say that person does not or
does have coronavirus. I would say probably once the peptides are fully
developed and we can immunize animals with them, there are many companies
that can do this rapidly. We should probably have an assay in three to four
months after those events occur.
Generex Biotechnology Corp. (GNBTQ) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
You know, every now and then, it's worth stepping out of the stock frenzy and diving into something as electrifying and far from the trading floor as Tomorrowland's latest Shanghai rendezvous. This ain't just any festival; it's the kind of hype that packs a punch—and frankly, it's a wild ride seeing such a spectacle set up shop in China, and sell out to boot. Partnering...
Continue Reading
AST SpaceMobile's Legal Tangle AST SpaceMobile, Inc. (NASDAQ:ASTS) finds itself neck-deep in legal quagmire, with a class action lawsuit looming large. Investors who snapped up ASTS securities between March 4, 2025, and July 15, 2026, have until November 13, 2026, to reckon their grievances before the courts. This is no joke, folks. If you've lost dough because of shaky...
Continue Reading
History's got chapters that stick with you, and the Long March is one of those stories that shake you to your core. It all started one October evening in 1934, when more than 86,000 soldiers from the Red Army found themselves on the banks of the Yudu River. It was a scene straight out of a novel: 800-odd boats held together with coffin boards and timber beams, all set to...
Continue Reading
A Fresh Chapter for Lundbeck's Board Leadership Lundbeck is sparking some fresh boardroom energy, and it's not just business as usual. Dorothea Wenzel, who's been steering the ship, is stepping down come 2027—AGM in sight. Now, in swings Lars Fruergaard Jørgensen, ready to grab the wheel. Yeah, we've got some seasoned pharma muscles flexing here. The Before and After:...
Continue Reading
Breaking Ground with Patient Representation Today's not-so-sunny forecast from Barcelona wasn't about the weather. United European Gastroenterology (UEG) rolled out its shiny new Patient Representatives Advisory Board (PRAB) during UEG Week 2026. This isn't just another committee on a never-ending list—it's a serious platform aimed at turning patient murmurs into a...
Continue Reading
Clock Ticking on AEVEX Lawsuit Participation Ah, the twists and turns of the stock market! AEVEX Corp. (NYSE: AVEX) finds itself knee-deep in a class action lawsuit, and investors have a mere 48 hours left to make their stand as the lead plaintiff. This legal saga stems from the company's April 2026 IPO and spills into the muddy waters of securities law violations....
Continue Reading
Antheia's Bold Move to Onshore Medicine Production Folks, when it comes to pharmaceuticals, it's about time someone started serious about keeping things closer to home. Antheia just landed a huge $80 million conditional commitment from the U.S. Department of War's Office of Strategic Capital. The fine print? This isn't just about building business—it's a play to secure...
Continue Reading
Top 5 Most Recently Viewed Articles
Quaker Chemical Faces Significant Market Challenges In a challenging market climate, Quaker Chemical Corporation (NYSE: KWR) recently saw its stock plummet to a 52-week low of $138.97. This specialty chemical company, renowned for its high-performance process fluids and coatings utilized in metalworking, has undergone considerable struggles over the past year, leading to...
Continue Reading
Aura Minerals Completes Acquisition of Bluestone Resources Aura Minerals Inc. (TSX: ORA) has successfully executed its acquisition of Bluestone Resources Inc. (BBSRF) through a strategic arrangement. This transaction signals a notable expansion for Aura as it aims to enhance its precious metals portfolio. Terms of the Acquisition Under the recent agreement, shareholders...
Continue Reading
Employee Benefits Marketing Transformation In the landscape of employee benefits, there lies a pressing need for innovation, especially regarding effective communication and marketing engagement. Businessolver, a recognized leader in HR and benefits technology, has taken significant strides with the introduction of its Benefits Communication and Automation Engine. This...
Continue Reading
Middlefield Canadian Income PCC Overview Middlefield Canadian Income PCC is a distinct investment option that focuses on providing income opportunities. Established as a protected cell company in Jersey, it adheres to well-defined regulatory standards, adding a layer of security for those who invest in it. Net Asset Value Insights In a recent evaluation, the estimated...
Continue Reading
Tarsus Pharmaceuticals Engages in Important Healthcare Conference Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) is committed to meeting unmet medical needs through innovative scientific advancements and cutting-edge technology. The company places a strong emphasis on eye care, with the goal of transforming the treatment landscape for patients. Recently, Tarsus announced...
Continue Reading
